Donepezil vs Ipilimumab

Donepezil vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Donepezil and Ipilimumab.

Mechanism of Action

Donepezil: Reversible acetylcholinesterase inhibitor.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Donepezil — 70 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Donepezil — C24H29NO3.

Molecular Weight: Donepezil — 379.4920 g/mol.

Type: Donepezil — Small molecule; Ipilimumab — Antibody.